• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Tuesday, October 27, 2026
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

Longer Radiotherapy Schedules Linked to Worse Cervical Cancer Survival

by
October 27, 2026
in Health
Reading Time: 3 mins read
0
Longer Radiotherapy Schedules Linked to Worse Cervical Cancer Survival

Longer Radiotherapy Schedules Linked to Worse Cervical Cancer Survival

Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

Women with cervical cancer who take longer to finish their definitive course of radiotherapy face measurably worse outcomes, according to a new systematic review and meta-analysis published in Frontiers in Oncology. Researchers from the First People’s Hospital of Jiande in Hangzhou, China, pooled data from nineteen studies covering 15,859 patients and found that prolonged overall treatment time was associated with poorer overall survival and a higher risk of the cancer returning within the treated area. Overall treatment time, or OTT, refers to the number of days from the first session of external-beam radiotherapy to the completion of the planned definitive radiotherapy course.

What has remained unclear is how large that penalty is, and whether it holds consistently across different treatment eras, including the modern era of concurrent chemoradiotherapy. To answer that question, the team searched PubMed/MEDLINE, Embase, Web of Science Core Collection, Scopus and the Cochrane Library from inception through August 1, 2026. Eligible studies had to assess OTT as either a categorical or continuous prognostic factor for patients receiving definitive radiotherapy or chemoradiotherapy for cervical cancer.

The authors appraised risk of bias with the Quality In Prognosis Studies tool and pooled time-to-event estimates as hazard ratios using random-effects models. The headline result came from ten independent cohorts that contributed to the primary overall survival analysis. Patients with prolonged OTT had a 61 percent higher hazard of death compared with those who completed treatment more quickly, with a pooled hazard ratio of 1.61 and a 95 percent confidence interval of 1.30 to 1.99.

The statistical heterogeneity between studies was substantial, with an I² value of 76 percent, meaning the individual studies varied considerably in the size of the effect they reported. Because cutoffs for defining prolonged treatment varied across studies, the researchers also ran a prespecified analysis limited to three independent cohorts that all used the same threshold: more than 56 days versus 56 days or fewer. Even within that narrower, more homogeneous comparison, the association persisted, with a hazard ratio of 1.16 (95 percent CI, 1.04 to 1.31) and low heterogeneity (I² = 37 percent).

Survival was not the only outcome affected. Prolonged OTT was also associated with a higher risk of local, pelvic or in-field failure, meaning the cancer recurring in or near the volume that received radiation. The pooled hazard ratio for this outcome was 1.80 (95 percent CI, 1.26 to 2.56; I² = 46 percent).

The authors reported that the overall survival association was consistent across subgroups defined by treatment era and by the source of the cutoff values used in each study, and that the finding remained robust in sensitivity analyses. As with any meta-analysis of observational prognostic studies, the results show association rather than proof of causation.

The Quality In Prognosis Studies assessment and the sensitivity analyses help address these concerns, but they cannot eliminate confounding entirely, and randomized evidence on deliberately shortening treatment schedules is not part of this synthesis. The findings therefore describe a consistent prognostic pattern across a large pooled population rather than a demonstrated causal effect of delay itself.

Even so, the practical message is straightforward and aligns with existing practice: every effort should be made to complete definitive radiotherapy without avoidable delays. For clinicians and patients alike, the 56-day interval remains a meaningful target, and the study provides quantitative backing for treating schedule adherence as an oncologic outcome in its own right rather than an administrative detail.

Subject of Research: Association between overall treatment time and oncologic outcomes after definitive radiotherapy or chemoradiotherapy for cervical cancer

Article Title: Overall treatment time and oncologic outcomes after definitive radiotherapy or chemoradiotherapy for cervical cancer: a systematic review and meta-analysis

Article References: Ruan, Y., Li, Y., Wu, D., Han, J., & Cheng, J. (2026). Overall treatment time and oncologic outcomes after definitive radiotherapy or chemoradiotherapy for cervical cancer: a systematic review and meta-analysis. Frontiers in Oncology, 16, Article 1969525. https://doi.org/10.3389/fonc.2026.1969525

Image Credits: AI Generated

DOI: 10.3389/fonc.2026.1969525

Keywords: cervical cancer, radiotherapy, chemoradiotherapy, overall treatment time, meta-analysis, systematic review, overall survival, hazard ratio, gynecologic oncology, treatment delays, prognosis, Overall

News Source: Nathaniel Bowman. (October 27, 2026). Longer Radiotherapy Schedules Linked to Worse Cervical Cancer Survival. Scienmag.

Tags: Cervical cancerchemoradiotherapygynecologic oncologyhazard ratioMeta-analysisOveralloverall survivaloverall treatment timeprognosisRadiotherapysystematic reviewtreatment delays
Share12Tweet7Share2ShareShareShare1

Related Posts

Gladstone Scientists Melanie Ott and Alex Marson Join National Academy of Medicine

Gladstone Scientists Melanie Ott and Alex Marson Join National Academy of Medicine

October 27, 2026
Airborne antibiotic-resistant ESKAPE bacteria detected at South African inner-city clinic

Airborne antibiotic-resistant ESKAPE bacteria detected at South African inner-city clinic

October 27, 2026

ORC1 Protein Rises with HBV Liver Disease Progression and Flags Poorer Survival

October 27, 2026

Zoledronic Acid Outcomes Reported in Ivorian Prostate Cancer Cohort

October 27, 2026

POPULAR NEWS

  • Tea Rhizosphere Fungi Show Ability to Break Down Tannin Compounds

    Tea Rhizosphere Fungi Show Ability to Break Down Tannin Compounds

    29 shares
    Share 12 Tweet 7
  • Gladstone Scientists Melanie Ott and Alex Marson Join National Academy of Medicine

    29 shares
    Share 12 Tweet 7
  • Airborne antibiotic-resistant ESKAPE bacteria detected at South African inner-city clinic

    29 shares
    Share 12 Tweet 7
  • Longer Radiotherapy Schedules Linked to Worse Cervical Cancer Survival

    29 shares
    Share 12 Tweet 7

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Tea Rhizosphere Fungi Show Ability to Break Down Tannin Compounds

Gladstone Scientists Melanie Ott and Alex Marson Join National Academy of Medicine

Airborne antibiotic-resistant ESKAPE bacteria detected at South African inner-city clinic

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 85 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.